Loading...

Top
Help
×

By creating an account you can:

Logo TaxTMI
Call Us / Help / Feedback

Contact Us At :

E-mail: [email protected]

Call / WhatsApp at: +91 99117 96707

For more information, Check Contact Us

FAQs :

To know Frequently Asked Questions, Check FAQs

Most Asked Video Tutorials :

For more tutorials, Check Video Tutorials

Submit Feedback/Suggestion :

Email :
Please provide your email address so we can follow up on your feedback.
Category :
Description :
Min 15 characters 0/2000
Make Most of Text Search
  1. Checkout this video tutorial: How to search effectively on TaxTMI.
  2. Put words in double quotes for exact word search, eg: "income tax"
  3. Avoid noise words such as : 'and, of, the, a'
  4. Sort by Relevance to get the most relevant document.
  5. Press Enter to add multiple terms/multiple phrases, and then click on Search to Search.
  6. Text Search
  7. The system will try to fetch results that contains ALL your words.
  8. Once you add keywords, you'll see a new 'Search In' filter that makes your results even more precise.
  9. Text Search
Add to...
You have not created any category. Kindly create one to bookmark this item!
Create New Category
Hide
Title :
Description :
❮❮ Hide
Default View
Expand ❯❯
Close ✕
🔎 News - Adv. Search
TEXT SEARCH:

Press 'Enter' to add multiple search terms. Rules for Better Search

Search In:
Main Text + AI Text
  • Main Text
  • Main Text + AI Text
  • AI Text
Category: ?
Categorized by AI
---- All Categories ----
  • ---- All Categories ----
  • Income Tax
  • GST
  • Customs, DGFT & SEZ
  • FEMA & RBI
  • Corp. Laws, SEBI & IBC
  • PMLA, Black Money & ED
  • Budget
  • News and Press Release
  • PTI News
Month:
---- All Months ----
  • ---- All Months ----
  • January
  • February
  • March
  • April
  • May
  • June
  • July
  • August
  • September
  • October
  • November
  • December
Year:
---- All Years ----
  • ---- All Years ----
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Sort By: ?
In Sort By 'Default', exact matches for text search are shown at the top, followed by the remaining results in their regular order.
Relevance Default Date
    President Trump wants to impose 15% tariff, up from 10% he announced after Supreme Court decision
    President Trump wants to impose 15 pc tariff, up from 10 pc he announced after Supreme Court decision
    Modi, Lula discuss US supreme court striking down reciprocal tariffs; set USD 30 bn annual trade target
    Global leaders, businesses pore over fallout of more US tariff swoons
    MP Congress targets Chouhan over Indo-US deal
    India now faces 10 pc tariffs in US for 150 days; govt says studying implications
    Working to expand preferential trade agreement with Mercosur bloc: Piyush Goyal
    Put India-US trade deal on hold, renegotiate terms: Congress
    Trade deal with US compromises India's interests in agriculture sector; farmers to suffer: Kejriwal
    Pharma exports up 9.4 pc in FY25; industry aims for double-digit expansion in 2026-27
    Vikas Coal and Minerals wins bid to operate Jalna dry port
    Indian govt weighs impact of US Supreme Court tariff ruling: Comm Min
    Govt studying developments on US tariff: Commerce min
    Best Crypto To Buy Now: DeepSnitch AI Teases Working AI Dashboard, Strengthening the Community’s 100x Bets, BNB and XRP Log Small Recoveries
    Facility for Withdrawal from Rule 14A
    India-US tariffs after Supreme Court verdict: An explainer
    Directorate General of Commercial Intelligence and Statistics Revises Base Year of Merchandise Trade Indices to FY 2022–23 to Reflect Current Trade ...
    MoSPI to Convene National Level Consultative Workshop on "Using Administrative Data for Governance: Harmonizing Departmental Data at State Level" on 2...
    Congress claims US trade deal has become an 'ordeal', Rahul says 'PM compromised'
❯❯
Maximize Maximize Maximize
0 / 200
Expand Note
Add to Folder

No Folders have been created

+

Are you sure you want to delete "My most important" ?

NOTE:

News
Showing Results for :
Reset Filters
Results Found:
Show All Summaries Hide All Summaries
February 21, 2026
Show AI Summary
Presidential tariff authority to impose global import taxes expanded via executive order, with temporary duration and statutory investigations.
The President announced an increase in a global import tariff implemented by an executive order designed to bypass ordinary congressional action and operate for a limited temporary period unless extended by legislation; concurrently, the administration is pursuing additional tariff measures under federal statutes that require Commerce Department investigations and administrative determinations.
February 21, 2026
Show AI Summary
Presidential tariff authority contested; executive order raises global import tariff after review of recent legal limitation.
After a judicial ruling that his emergency powers did not authorize sweeping tariffs, the President signed an executive order bypassing Congress to impose a temporary global import tax limited to 150 days unless extended by legislation; following review of the court decision he announced an upward adjustment to the proposed global tariff rate.
February 21, 2026
Show AI Summary
Reciprocal tariffs: leaders agree to study implications and adopt a wait-and-watch approach while boosting strategic trade ties.
Discussion focused on the trade-policy implications of a major US decision affecting reciprocal tariffs, with both leaders adopting a "wait-and-watch" posture to study potential US administrative responses. Parallel measures included a pact on critical minerals to build resilient supply chains, a joint digital partnership declaration, and multiple MoUs covering mining, MSMEs, healthcare, defence maintenance cooperation, and technology and energy collaboration.
February 21, 2026
Show AI Summary
Tariff invalidation prompts review of affected duties, potential refund claims, and continued uncertainty from proposed new tariff measures.
Invalidation of certain executive-era import duties removes the legal basis for specified tariff measures and creates potential refund claims by importers and foreign suppliers, while other tariffs tied to distinct statutory or product-specific authorities remain in force. Governments and businesses must distinguish between invalidated and continuing duties when reviewing compliance, pursuing restitution, and adapting contractual and supply chain plans amid the added uncertainty of proposed new tariff measures under alternative rules.
February 21, 2026
Show AI Summary
Trade agreement criticised as threatening farmers' livelihoods and spurring nationwide farmer protests and political agitation.
The state Congress contends the interim Indo US trade agreement will expose Indian farmers to damaging import competition-particularly in soybean and cotton-depress domestic prices, threaten small traders and related industries, and amount to a surrender of national agricultural interests. It has announced coordinated protests and gatherings (Kisan Sammelans, chaupals, marches) in Bhopal, Budhni and Vidisha, blaming the Union Agriculture Minister for failing to defend farmers and urging mobilisation to protect rural livelihoods.
February 21, 2026
Show AI Summary
Temporary import surcharge alters global trade rules, reshaping US-India tariff calculus and prompting reassessment of bilateral negotiations.
A temporary import surcharge has been proclaimed under Section 122 of the Trade Act of 1974 as a time limited global ad valorem levy effective February 24, operating in addition to existing MFN and import duties and excluding specified products. The measure alters the tariff calculus for India by reducing the immediate reciprocal tariff burden relative to prior higher levies while creating uncertainty about post period tariffs; the Indian government is studying implications as bilateral trade talks continue and stakeholders call for renegotiation and sectoral protections.
February 21, 2026
Show AI Summary
Preferential trade agreement expansion aims to broaden tariff coverage and deepen investment, technology and critical minerals cooperation India Mercosur
Expansion of the India Mercosur preferential trade agreement aims to convert a limited pact covering 450 tariff lines into a full agreement to improve market access, grow bilateral investment and foster technology partnerships. The parties set an enhanced annual trade target and signed a cooperation pact on critical minerals to support downstream processing and collaboration. Priority sectors include defense, energy and renewables, agri and agrochemicals, health and pharma, aerospace, automotive, semiconductors and digital technology, alongside measures to attract investment and ease business through visa facilitation and domestic reforms.
February 21, 2026
Show AI Summary
Trade Agreement Suspension: call to halt and renegotiate interim India-US deal to protect farmers after US tariff invalidation.
The article demands suspension and renegotiation of the interim India-US trade framework to protect farmers, asserting the Framework cannot be implemented following judicial invalidation of presidential tariff powers and the administration's subsequent reliance on alternative tariff measures; it requires the government to commit to no import liberalisation on agricultural products, to review the agreement's haste and sustainability, and to safeguard non tariff protections and domestic livelihoods pending clarifications.
February 21, 2026
Show AI Summary
Trade tariff changes threaten agricultural export competitiveness and expose domestic farmers to cheaper foreign imports.
An interim trade agreement reduces previously higher reciprocal US duties on Indian imports to a lower tariff level while lowering or eliminating duties on certain US agricultural imports into India, a realignment presented as likely to raise prices of Indian farm exports in the US and to increase competitiveness of US products domestically, threatening export opportunities for maize, soybean, dairy, peanut and cotton producers and exposing domestic farmers to cheaper US imports.
February 21, 2026
Show AI Summary
Pharma exports: government and industry focus on market access and trade engagement to boost competitiveness and growth.
The commerce ministry and industry discussed measures to sustain and accelerate pharmaceutical exports, focusing on enabling conditions, resolving trade bottlenecks, and coordinated engagement with exporters, regulators, and Indian Missions. Strategic trade engagements with major partners were identified to improve market access, competitiveness, and regulatory compliance, supporting industry aims for double-digit expansion.
February 21, 2026
Show AI Summary
Customs port status enables Jalna dry port to commence import-export operations after award of long-term operating mandate.
The National Highway Authority accepted Vikas Coal and Minerals Pvt. Ltd.'s bid to operate the Jalna Dry Port under a long-term operating mandate, subject to completion of administrative approvals and bank guarantee formalities; the operator will pay an annual, turnover-based fee. The facility has received customs port status, enabling import-export and customs processing, and essential infrastructure including a cargo terminal and a dedicated rail connection is operational, supporting imminent commencement of operations.
February 21, 2026
Show AI Summary
Presidential tariff authority curtailed; temporary import surcharge imposed alters bilateral tariff treatment and prompts trade talks.
Presidential tariff authority was found to have been exceeded when broad import levies were imposed; an executive proclamation subsequently announced a temporary import surcharge that modifies effective tariffs and operates in addition to existing MFN or import duties, prompting review of legal and commercial consequences and informing ongoing bilateral trade negotiations.
February 21, 2026
Show AI Summary
Tariff ruling prompts government review of international trade measures and potential policy implications for exporters and customs operations.
The government is assessing recent developments on US tariff measures after a judicial decision and an executive statement, and is studying announced administrative steps to evaluate implications for trade policy, tariff administration, and customs procedures.
February 21, 2026
Show AI Summary
Global tariffs may trigger market sell-offs, increasing interest in presale crypto assets with perceived volatility protection.
Announcement of renewed global tariffs and the Supreme Court's limitation on tariff authority are presented as macro drivers likely to increase market volatility, prompting traders to seek presale tokens. The article promotes DeepSnitch AI-citing reported presale funds raised, a preview of a dashboard powered by five AI agents, and an LLM-style DYOR risk-assessment tool-as a presale asset positioned to mitigate short-term swings; it contrasts this with BNB and XRP, which show modest recoveries but remain vulnerable to downside scenarios.
February 21, 2026
Show AI Summary
Withdrawal from Rule 14A registration: online opt out with Aadhaar authentication and specified return conditions required.
Enables electronic withdrawal from Rule 14A by filing Form GST REG-32 on the GST Portal: eligible active taxpayers must select the opt out option, state a reason, and complete Aadhaar authentication for the primary authorised signatory and at least one promoter/partner; ARN is issued only after successful authentication. Filing requires meeting return filing preconditions and completion of draft submission and authentication within specified timelines. While REG 32 is pending, certain amendments and self cancellation are barred. After issuance of Form GST REG-33, taxpayers must report output tax liability on supplies to registered persons exceeding the prescribed threshold.
February 21, 2026
Show AI Summary
Trade tariffs: US issues new global import levy after court ruling, altering reciprocal duties and exporter compliance obligations.
The Supreme Court's invalidation of the prior tariff framework prompted an executive proclamation establishing a new global import surcharge, producing a uniform temporary levy that recalibrates reciprocal duties on foreign exporters and requires exporters and advisors to reassess customs, contractual and compliance implications under the revised tariff regime.
February 21, 2026
Show AI Summary
Reciprocal tariffs transformed into temporary import surcharge, altering tariff exposure and prompting reassessment of bilateral trade concessions.
The US proclamation replaces varied reciprocal tariffs with a uniform temporary import surcharge of 10 per cent ad valorem applied in addition to MFN duties on goods previously covered under reciprocal tariffs. Indian exports will therefore bear MFN duties plus the temporary surcharge rather than the earlier country specific reciprocal or punitive levies; certain sectoral tariffs remain in force and specified categories of goods are exempted from the temporary surcharge. The change is contemporaneous with negotiations on an initial bilateral trade agreement, prompting a reevaluation of tariff concessions.
February 21, 2026
Show AI Summary
Merchandise trade indices base year revision updates weights, classifications and methodology to reflect current trade structure and improve comparability.
DGCI&S has revised the merchandise trade indices to base FY 2022-23 to reflect current trade composition, updating commodity baskets and month-specific weights based on base-year trade values. The revised series incorporates monthly, quarterly and annual Export/Import Unit Value and Quantity Indices, Principal Commodity, SITC and BEC classifications, bilateral and region-wise indices for top partners, and Gross, Net and Income Terms of Trade. Methodological refinements cover common commodity-basket selection, imputation of missing unit values and Laspeyres-type weighted averaging; comparability is meaningful mainly for same-month comparisons across years. Detailed methods and data will be published by DGCI&S.
February 21, 2026
Show AI Summary
Administrative data harmonization to inform a national agenda and prepare states for coordinated governance reforms.
The Ministry of Statistics and Programme Implementation is convening a national consultative workshop on using administrative data for governance to brief States/UTs, Central ministries and other stakeholders on objectives, scope and key issues, as a preparatory step for a national summit. The workshop will gather expert deliberations, showcase use cases, and collate inputs from State level workshops to identify priority reform areas for strengthening administrative data systems and enabling responsible harmonization across departments.
February 21, 2026
Show AI Summary
Presidential tariff authority reversed, trade deal's tariff basis challenged; India-US agreement's viability questioned, prompting political backlash domestically.
Following a judicial curtailment of presidential power to impose global tariffs under emergency authority, the US administration invoked an alternative statute to impose a temporary import surcharge to preserve an existing India-US interim trade framework; this shift alters the tariff basis of the deal and raises questions about the surcharge's applicability to India and the deal's implications for market access, subsidy withdrawal, agricultural protections, energy security, and data safeguards.

News

Back

All News

Showing Results for :
Reset Filters
No Records Found

News

Back

All News

Showing Results for : Reset Filters
Customs & Trade

Built on Service, Trust and Quality: How Alpex Pharma Became the Manufacturing Partner Pharma Brands Rely On

March 19, 2026

Contents
Summary
Note

Note

-

Bookmark

Print

Print

With a multi-certified, multi-division manufacturing infrastructure and an established presence across domestic and international markets, Alpex Pharma is setting a new benchmark for what third-party pharmaceutical manufacturing should look like in India. INDIA — The Indian pharmaceutical industry stands at a defining moment. Domestic demand is surging, regulatory standards are tightening, and Indian-made medicines are earning growing respect in markets across Asia, Africa, and beyond. At the centre of this transformation is a quiet but powerful engine — the contract manufacturer. And few have positioned themselves for this moment as deliberately, or as decisively, as Alpex Pharma. Under the leadership of Director Shubham Mittal, Alpex Pharma has built a manufacturing organisation that bears none of the hallmarks of a conventional contract facility. It operates with the systems, the certifications, the infrastructure, and the service philosophy of an enterprise that was designed from the outset to support pharma brands at scale — domestically and globally. A Manufacturing Organisation Built for Regulated Markets At the foundation of Alpex Pharma’s operations is a quality infrastructure that meets and exceeds the standards of the world’s most demanding pharmaceutical regulatory frameworks. The company holds WHO-GMP, GMP, GLP, and Ghana-GMP certifications — the gold standard combination for manufacturers supplying both India’s domestic market and regulated international markets. The addition of Ghana-GMP accreditation signals something beyond compliance. It reflects a strategic commitment to international manufacturing standards and demonstrates that Alpex Pharma’s quality systems have been independently verified against the requirements of export-destination regulators — not just domestic ones. For brand partners with global ambitions, this distinction matters enormously. Global Reach Through Strategic Partnerships Alpex Pharma enables pharma brands to access international markets through established neutral code manufacturing partnerships — producing under partner brand identities across multiple geographies. This infrastructure allows brand owners to expand globally without the capital investment of building their own international supply chain. Specialist Divisions. Enterprise-Grade Separation. One of the clearest indicators of a manufacturer’s true capability is not its equipment list — it is how it organises itself. Alpex Pharma operates across three dedicated, fully separated manufacturing divisions, each purpose-built for its product category with the infrastructure, containment protocols, and compliance architecture it demands. • General Division : Tablets, capsules across a broad therapeutic range, serving domestic and export markets with full GMP compliance. • Beta-Lactam Division : Dedicated Beta-Lactam manufacturing with full containment, regulatory separation and specialist protocols for sensitive antibiotic classes. • Cephalosporin Division : Isolated Cephalosporin production infrastructure meeting the highest standards of cross-contamination prevention and regulatory compliance. This level of divisional separation is not common among Indian contract manufacturers. It reflects an investment in doing things properly — the kind of structural commitment that enterprise pharma clients, institutional buyers, and international regulators look for when evaluating a manufacturing partner for the long term. “Quality is not a stage in our production process. It is the architecture of eveAlpexng we build — every division, every system, every client relationship.” — Shubham Mittal, Director, Alpex Pharma The Standard That Sets Alpex Pharma Apart What distinguishes Alpex Pharma in a crowded contract manufacturing landscape is not any single certification or facility specification. It is the consistent experience of every brand that works with the company — an experience defined by reliability, transparency, and a service culture that treats each client’s business as seriously as its own. Alpex Pharma’s account management model is built on dedicated partnerships. Brand owners are not passed between teams or managed through a generic helpdesk. They work with a dedicated team that understands their product portfolio, their market, their regulatory requirements, and their commercial timelines — and is accountable for all of it. Production scheduling is built around the client’s launch windows and distribution cycles. And delivery commitments, once made, are treated as non-negotiable. This is the operational definition of service, trust and quality — not as corporate values on a wall, but as the daily practice of a manufacturing organisation that has built its entire reputation on them. It is also precisely why Alpex Pharma has become the top third-party manufacturer of choice for pharma brands across India and international markets. “We do not want to be the largest manufacturer in the room. We want to be the most trusteAlpex PharmaIndia’s that every brand in our portfolio would recommend without hesitation.” — Shubham Mittal, Director, Alpex Pharma India’s Pharma Ambition Needs Partners Like This India’s contract manufacturing sector is undergoing a generational shift. The brands emerging from this market are more sophisticated, more globally ambitious, and more discerning about their supply chain partners than any previous generation. They are not looking for the cheapest option. They are looking for the most reliable one — a manufacturing partner whose quality systems, international credentials, service culture, and operational discipline can match their own ambitions and protect their brand as they grow. Alpex Pharma has positioned itself squarely in that space. Not as a commodity contract manufacturer competing on price, but as a quality-led enterprise competing on performance. With internationally recognised certifications, enterprise-grade divisional infrastructure, established global export pathways, and a service philosophy rooted in genuine partnership, the company represents a new standard for what third-party pharmaceutical manufacturing can and should be in India. The pharmaceutical brands that choose Alpex Pharma are not simply outsourcing production. They are gaining a manufacturing partner with the capability, the credentials, and the commitment to grow with them — wherever that growth takes them. About Alpex Pharma Alpex Pharma is a leading third-party pharmaceutical manufacturer based in India, holding WHO-GMP, GMP, GLP, and Ghana-GMP certifications. Operating across three specialist divisions — General, Beta-Lactam, and Cephalosporin — the company serves pharma brands in domestic and international markets with a commitment to quality, reliability, and partnership. For more information, visit www.alpexpharma.in. Media Contact Alpex Pharma — Communications Email: [email protected] Website: www.alpexpharma.in (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR

Topics

Acts Income Tax